Clinical Trial Update: Daratumumab in Immune-mediated Thrombotic Thrombocytopenic Purpura

View source ↗

Summary

A clinical trial evaluating daratumumab for acquired immune-mediated thrombotic thrombocytopenic purpura is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thrombotic Thrombocytopenic Purpura Acquired

Drugs mentioned

• DARZALEX (daratumumab)

Snippet

Sponsor: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | Conditions: Thrombotic Thrombocytopenic Purpura, Acquired | Status: RECRUITING